Cingulate Inc. Operating Lease Liability
Cingulate Inc. (CING) had Operating Lease Liability of $1.34 million as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-18
- 2025-12-31: Operating Lease, Liability $1.34M.
- 2024-12-31: Operating Lease, Liability $130.66K.
- 2023-12-31: Operating Lease, Liability $488.75K.
- 2022-12-31: Operating Lease, Liability $828.50K.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $1.34M 10-K · filed 2026-03-18 |
| 2024-12-31 | $130.66K 10-K · filed 2026-03-18 |
| 2023-12-31 | $488.75K 10-K · filed 2025-03-27 |
| 2022-12-31 | $828.50K 10-K · filed 2024-04-01 |
| 2021-12-31 | $1.12M 10-K · filed 2023-03-10 |
| 2020-12-31 | $1.29M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |